Charles Elliott Sigal
Charles Elliott Sigal's purchase track record
Charles Elliott Sigal has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/1/2023 | VIR | $57K | +18.0% | -42.9% | +14.3% |
| 1/3/2023 | VIR | $190K | -6.5% | -2.1% | +16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Transaction History
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/27/2026 | View on chart |
| ALNY | ▲ Buy | Grant | 671 | $0 | 5/20/2026 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/30/2025 | View on chart |
| ALNY | ▲ Buy | Grant | 775 | $0 | 5/8/2025 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/30/2024 | View on chart |
| VIR | ▲ Buy | Grant | 6,027 | $0 | 5/22/2023 | View on chart |
| VIR | ▲ Buy | Open Market | 2,500 | $57K | 3/1/2023 | View on chart |
| VIR | ▲ Buy | Open Market | 2,500 | $62K | 1/5/2023 | View on chart |
| VIR | ▲ Buy | Open Market | 2,500 | $63K | 1/4/2023 | View on chart |
| VIR | ▲ Buy | Open Market | 2,500 | $64K | 1/3/2023 | View on chart |
| VIR | ▲ Buy | Grant | 6,405 | $0 | 5/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates
Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.